Instituto do Câncer e Transplante de Curitiba ( Site 0611)

Curitiba, Paraná 80510130

0 studies enrolling now · 1 studies all time

What they study most

Hematological Malignancies

Studies at this site

• A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) — Completed